Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil

38Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

From September 2005 to March 2007, 238 individuals being vaccinated for the first time with the yellow fever (YF) -17DD vaccine were enrolled in a cohort established in Recife, Brazil. A prospective study indicated that, after immunization, anti-YF immunoglobulin M (IgM) and anti-YF IgG were present in 70.6% (IgM) and 98.3% (IgG) of the vaccinated subjects. All vaccinees developed protective immunity, which was detected by the plaque reduction neutralization test (PRNT) with a geometric mean titer of 892. Of the 238 individuals, 86.6% had IgG antibodies to dengue virus; however, the presence of anti-dengue IgG did not interfere significantly with the development of anti-YF neutralizing antibodies. In a separate retrospective study of individuals immunized with the 17DD vaccine, the PRNT values at 5 and 10 years post-vaccination remained positive but showed a significant decrease in neutralization titer (25% with PRNT titers < 100 after 5 years and 35% after 10 years). Copyright © 2011 by The American Society of Tropical Medicine and Hygiene.

Figures

  • Figure 1. Regions in Brazil where YF vaccination is recommended. Source: SVS/MS, Brazil.
  • Table 1 Detection of YFV-specific IgM and IgG antibodies according to the time of sample collection ( N = 238)
  • Figure 2. Comparison of YFV IgG index between anti-dengue– positive and -negative individuals after YF-17DD vaccination ( N = 238).
  • Table 2 Follow-up of neutralization titer after YF-17DD vaccination (2005–2009)
  • Figure 4. Neutralization antibody titers 5 and 10 years after YF-17DD vaccination ( N = 40).
  • Figure 3. Comparison of neutralization antibody titers between anti-dengue–positive and -negative individuals after YF-17DD vaccination ( N = 238).

References Powered by Scopus

A simple method of estimating fifty per cent endpoints

18047Citations
N/AReaders
Get full text

Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses.

1369Citations
N/AReaders
Get full text

Yellow fever: An update

440Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Review article: Efficacy and duration of immunity after yellow fever vaccination: Systematic review on the need for a booster every 10 years

173Citations
N/AReaders
Get full text

17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study

95Citations
N/AReaders
Get full text

Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day

89Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Barbosa De Melo, A., Da Silva, M. D. P. C., Magalhães, M. C. F., Vega Gonzales Gil, L. H., Freese De Carvalho, E. M., Braga-Neto, U. M., … Tenório Cordeiro, M. (2011). Description of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil. American Journal of Tropical Medicine and Hygiene, 85(4), 739–747. https://doi.org/10.4269/ajtmh.2011.10-0496

Readers over time

‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘240481216

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 29

64%

Researcher 12

27%

Professor / Associate Prof. 2

4%

Lecturer / Post doc 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 18

42%

Agricultural and Biological Sciences 15

35%

Biochemistry, Genetics and Molecular Bi... 6

14%

Immunology and Microbiology 4

9%

Save time finding and organizing research with Mendeley

Sign up for free
0